|  |  |  |  |
| --- | --- | --- | --- |
| **Variable** | **Total** | **Supratentorial** | **Infratentorial** |
| **Mean age at BM diagnosis (SD)** | 60.5 (9.84) | 60.3 (9.84) | 60.8 (10.0) |
| **Sex (%)** |  |  |  |
| Male | 34 (40.0%) | 20 (32.8%) | 14 (58.3%) |
| Female | 51 (60.0%) | 41 (67.2%) | 10 (41.7%) |
| **BM region (%)**  **Patient status as of 21/04/2020 (%)** | - | 61 (71.8%) | 24 (28.2%) |
| Deceased | 65 (76.5%) | 47 (77.0%) | 18 (75.0%) |
| Alive | 20 (23.5%) | 14 (23.0%) | 6 (25.0%) |
| **Primary cancer origin (%)** |  |  |  |
| Lung | 46 (54.1%) | 38 (62.3%) | 8 (33.3%) |
| Breast | 14 (16.5%) | 9 (14.8%) | 5 (20.8%) |
| Kidney  Colorectal  Oesophageal  Gynaecological  Unknown  Suprarenal  Prostate gland  Liver  **Mean KPS at diagnosis (SD)**  **Mean KPS after resection (SD)**  **Timing of presentation (%)**  Metachronous  Synchronous  **Extent of resection (%)**  Subtotal  Gross total  **Post-operative complications (%)**  None  Neurological  Non-neurological  Neurological and non-neurological  **Adjuvant therapy use (%)**  None  Stereotactic radiotherapy  Whole brain radiotherapy  **Active extracranial disease (%)**  No  Yes  **Local BM recurrence (%)**  No  Yes  **BM recurrence in other brain areas (%)**  No  Yes | 7 (8.24%)  6 (7.06%)  3 (3.53%)  3 (3.53%)  3 (3.53%)  1 (1.18%)  1 (1.18%)  1 (1.18%)  88.3 (11.1)  86.8 (13.8)  50 (58.8%)  35 (41.2%)  44 (51.8%)  41 (48.2%)  63 (74.1%)  13 (15.3%)  7 (8.24%)  2 (2.35%)  70 (83.3%)  11 (13.1%)  3 (3.57%)  17 (20.2%)  67 (79.8%)  35 (42.7%)  47 (57.3%)  60 (73.2%)  22 (26.8%) | 6 (9.84%)  3 (4.92%)  1 (1.64%)  2 (3.28%)  1 (1.64%)  0 (0.0%)  1 (1.64%)  0 (0.0%)  87.8 (11.8)  86.1 (13.0)  37 (60.7%)  24 (39.3%)  30 (49.2%)  31 (50.8%)  50 (82.0%)  8 (13.1%)  1 (1.64%)  2 (3.29%)  49 (81.7%)  8 (13.3%)  3 (5.00%)  13 (21.7%)  47 (78.3%)  22 (36.7%)  38 (63.3%)  42 (70.0%)  18 (30.0%) | 1 (4.17%)  3 (12.5%)  2 (8.33%)  1 (4.17%)  2 (8.33%)  1 (4.17%)  0 (0.0%)  1 (4.17%)  90.0 (8.45)  89.3 (16.4)  13 (54.2%)  11 (45.8%)  14 (58.3%)  10 (41.7%)  13 (54.2%)  5 (20.8%)  6 (25.0%)  0 (0.0%)  21 (87.5%)  3 (12.5%)  0 (0.0%)  4 (16.7%)  20 (83.3%)  13 (59.1%)  9 (40.9%)  18 (75.0%)  4 (25.0%) |

**Table I** Data for 85 patients undergoing resection for brain metastases between February 2014 and August 2019